мане (Рипутуре) GIONA	ruentes-			_			Juile 23,	2000
Name (Print/Type) Gloria	Fuentee	· · · · · · · · · · · · · · · · · · ·	(Attorney/	ngeni)		Date	June 29,	
Signature AM	TONY		Registrati (Attorney/		47,580	Telephone	(617) 951	-7000
SUBMITTED BY	7							
Non-English Specific Other (e.g., late filing				nation E	Disclosure	e Statement	180	.00
4. OTHER FEE(S)							Fees P	aid (\$)
<u>Total Sheets</u> - 100 =	Extra Sheets	Number of ea	ch additional (round u				Fee Pa	nid (\$)
If the specification and listings under 37 CF	drawings exc FR 1.52(e)), th	e application size fe U.S.C. 41(a)(1)(G)	e due is \$250 and 37 CFR) (\$125 1.16(s).	for small o	entity) for each	r computer additional 50	
-3 = 3. APPLICATION SIZE I	×			_				
Indep. Claims Ex	tra Claims		ee Paid (\$)					
- 20 =	X	=				ee (\$)	Fee Paid (\$)	
Multiple dependent claim Total Claims Ext	ms tra Claims	Fee (\$) F	ee Paid (\$)		N	lultiple Depend	360 lent Claims	180
Each independent claim	-	ding Reissues)					200	100
Each claim over 20 (incl	luding Reissu	es)					50	25
2. EXCESS CLAIM FEE: Fee Description	3						Fee (\$)	Fee (\$)
Provisional	200	100	0	0	0	0		mall Entity
Reissue	300			250	600	300		
Plant	200			50	160	80		
Design	200	• "	00	50	130	65		
Utility	300	150 5	00 2	.50	200	100		
Application Type	FiLi <u>Fee (\$)</u>	Small Entity	<u>Smal</u>	EES I Entity e (\$)	Fee (\$)	Small Entity	Fees Pa	<u>id (\$)</u>
1. BASIC FILING, SEAR	•		SEARCH F	FFS	FXAMII	NATION FEES	3	
FEE CALCULATION		· ·						
fee(s) und	er 37 CFR 1.1	e(s) or underpayment 6 and 1.17	x x	Credit	any overp	ayments		
x Charge fee	• •			,	, ,	dicated below, e	except for the	filing fee
For the above-ide	entified deposi	it account, the Directo	or is hereby a	٦				
X Deposit Account D	eposit Account Nu	mber: 18-1945 Deposit	Account Name:	Fisl	h & Neav	e IP Group, R	opes & Gray	LLP
Check Credit	t Card	Money Order	None	Other (please iden	tify):		
METHOD OF PAYME	NT (check al	I that apply)						
TOTAL AMOUNT OF PA	· · · · · · · · · · · · · · · · · · ·	(\$) 180.00		Docket	No.	WIBL-P01-54	9	
Applicant claims sn	nall entity status	. See 37 CFR 1.27	Art Unit		<u> </u>	1631		-
Fo	r FY 200)5	-	med inver		John Brusca	is wairiy	
FEETK	ANSIV	IIIIAL				September 19 Sridhar Rama	•	
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL				7.50.000.00.7.10		09/955920		
Effective on 12/08/2004.				Complete if Known				
der the Paperwork Reduction Act of 1995, no person are required to re				U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it displays a valid OMB control number.				
<i>₹</i> /			11	S Patent		roved for use through		

in an envelope addressed to: MS	dence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV669635557US, Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
shown below.	Λ , Λ
Dated: <u>June 29, 2006</u>	Signature:

I her by certify that this correspondence is being deposited with the U.S. Postal solice as Express Mail, Airbill No. EV669635557US, in an envelope addressed MS Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 29, 2006 Signature:

Docket No.: WIBL-P01-549

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ramaswamy et al.

Application No.: 09/955,920

Confirmation No.: 9860

Filed: September 19, 2001

Art Unit: 1631

For: GENETIC MARKERS FOR TUMORS

Examiner: John Brusca

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

07/05/2006 EAYALEW1 00000021 181945 09955920

01 FC:1806

180.00 DA

Application No.: 09/955,920 Docket No.: WIBL-P01-549

Applicant submits herewith a copy of the single reference listed on the attached PTO/SB/08 form.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 18-1945 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-549. A duplicate copy of this paper is enclosed.

Dated: June 29, 2006

Respectfully submitted,

Glória Fuentes

Registration No.: 47,580

FISH & NEAVE IP GROUP, ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 09/955,920 SUPPLEMENTAL INFORMATION Filing Date September 19, 2001 **DISCLOSURE** First Named Inventor Sridhar Ramaswamy 1631 STATEMENT BY APPLICANT C. Mahatan **Examiner Name** Sheet 1 of 1 Attorney Docket Number WIBL-P01-549

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	⊤ ⁵

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
·	CC	MIKLOS and MALESZKA, 2004, Microarray reality checks in the context of a complex disease, Nature Biotechnology 22(5):615-621	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date Signature Considered			
Signature Considered	Examiner	Date	
	Signature	Considered	1_

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached